Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide with radiotherapy for unfavorable intermediate-risk prostate cancer
2022-002431-53Phase 2Active
- Sponsor
- Institut Bergonié
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of darolutamide in prostate cancer (PCa) (2 arms), sponsored by Institut Bergonié. Primary endpoint: Biological response at 6 months. Started Jun 2024; status: active.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2022-002431-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002431-53.